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Abstract: 
Background: Multiple myeloma may involve the nervous system at every level, including the 
neuromuscular junction, peripheral nerve, plexus, spinal nerve root, spinal cord, meninges, and 
brain. Such involvement may be primary or secondary, as well as non-invasive paraneoplastic 
effects. 
Objective: To find out the perevalence and pattern of CNS manifestations in Sudanese patients 
with multiple myeloma seen in Al-Shaab Teaching Hospital and Khartoum Nuclear Hospital. 
Methodology: This is a prospective descriptive cross sectional, hospital based study. It was 
conducted in Al-Shaab Teaching Hospital and Khartoum Nuclear Hospital in the period from 
June2009 to June 2010. 50 patients with multiple myeloma were included in the study. 
Results: Males were more than females with ratio of 2.8:1. The common (36%) age of presentation 
was between 55-64 years. There was increased incidence of multiple myeloma in patients from the 
west of Sudan. Farmers and free workers had high incidence of multiple myeloma (34% and 27% 
respectively). The study demonstrated that the most common non- neurological symptoms was 
locomotor symptoms (24%) ,while the most common  neurological symptoms were backache  and 
neck pain .The most common neurological findings were cord compression (8%) followed by 
peripheral neuropathy (2%) and CVA (2%). 22% of patients completed treatment with good 
response, 12% with partial response, 18% with no response and 48% are still on treatment. 
Conclusion: CNS involvement among our studied group was not uncommon. 
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ULTIPLE myeloma (MM) is 
characterized by the neoplastic 
proliferation of a single clone of 
plasma cells in the boon marrow producing a 
monoclonal immunoglobulin1, 2. This 
proliferate results in boon abnormalities that 
may lead to pathologic fractures3, 4. Anemia 
and hypercalcemia ending with renal 
insufficiency; are among the common clinical 
findings. However, patients are predisposed 
to bacterial infections and bleeding  
tendency5, 6. MM may involve the nervous 
system at every level, including the 
neuromuscular junction, peripheral nerves, 
spinal    nerves roots, spinal cord, meninges 
and brain7, 8. Common neurological 
complications in patients with MM include 
radiculopathy and spinal cord compression, 
usually in the thoracic or lumbosacral area, 
resulting from compression by plasmacytoma 
or collapsed bone. Peripheral neuropathy is 
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To describe the pattern of CNS manifestations 
of MM among Sudanese patients seen in Al-
shaab Teaching Hospital and Khartoum 




This is a prospective, descriptive, cross-
sectional, hospital-based study. It was 
conducted in Al-Shaab Teaching Hospital and 
Khartoum Nuclear Hospital in the period 
from June 2009 to June 2010. Al Shaab 
Teaching Hospital is a tertiary hospital, 
located in the centre of Khartoum town. There 
are two neurological units with 43 beds and 
two neurosurgical units with 50 beds, there 
are three intensive care units, two neurology 
referred    clinics   and    three    neurosurgery  
M 
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referred clinics each week. Khartoum Nuclear  
Hospital is a tertiary hospital, located in the 
centre of Khartoum town. It is the biggest 
center in Sudan for chemotherapy, 
radiotherapy and management of cancer 
related diseases.  
Inclusion criteria: (1) Sudanese patients 
admitted during that time and diagnosed as 
multiple myeloma. (2) Those who agreed to 
participate in the study. 
All patients gave verbal or written consent to 
participate in this study. The study was 
approved by the local ethics committee. 
Exclusion criteria: patients with multiple 
myeloma and HIV.  
Data collection and analysis: Data were 
retrieved from the patients or close relatives 
using anonymous questionnaire. Detailed 
history was taken and through clinical 
examination was performed for each patient. 
Investigations done for patients include: urine 
analysis, hemoglobin, TWBC, ESR, urine for 
Bence Jones protein, renal function test, 
serum protein, serum calcium, X-rays (skull, 
vertebrae, ribs ), bone marrow aspiration and 
biopsy, plasma protein electrophoresis, brain 
CT, MRI spine and if needed EMG and NCS. 





Fifty patients fulfilled inclusion criteria and 
were enrolled in the study. The common age 
(36%) of presentation was between 55-64 
years (Table1). 
 
Table 1: Showed age distribution among 50 
Sudanese patients with multiple myeloma.  
 
age Frequency (%) 
35-44 3 (6) 
45-54 9 (18) 
55-64 18 (36) 
65-74 13 (26) 
>75 7 (14) 
 
Males (74%) were more than females (26%) 
(ratio2.8:1). They were coming from different 


















The study showed that farmers and free 
workers had higher incidence of multiple 
myeloma (61%). 
 
Non neurological symptoms involved the skin 
and locomotor symptoms that constituted 
24% each, renal symptoms 20%, GIT 
symptoms 12% and cardiovascular  
symptoms 12%.  
Table 2 shows distribution of neurological 
symptoms. It was found that backache and 
neck pain were the common presenting 
symptoms (38%). The neurological diagnoses 
were illustrated in figure 2. 
 
Table2: Distribution of neurological 
symptoms. 
 
symptom Frequency (%) 
Head ache 8 (16) 
Convulsions 0 (0) 
Loss of consciousness 0 (0) 
Limb weakness+ numbness 6 (12) 
Back ache + neck pain 19 (38)
Sphincteric disturbances 2 (4) 
Muscle pain 7 (14) 
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It was found that 29% of the patients had low 
haemoglobin, 22% had high ESR, 70% had 
high serum calcium, 20% had high renal 
function test and 62% had high serum protein. 
It did appear that 24% (14% with 
neurological manifestations) of the patients 
had Bence Jones protein in their urine.  It was 
found that 62% had high total serum protein. 
It did appear that 22% of patients with 
neurological manifestations had high serum 
protein while 40% of patients without 
neurological manifestations had high serum 
protein. X-ray (skull, vertebrae, ribs) 
abnormalities among the patients showed that 
66% had lytic lesions. It was noticed that 24% 
of patients with neurological manifestations 
had lytic lesions while 42% of patients 
without neurological manifestations had lytic 
lesions. The study showed that 22% of the 
patients complete treatment with good 














Similar to what was reported by other 
researchers; word wide the study showed that 
males were affected more than females11-13. 
Like others it was found that the common age 
of presentation was between 55-64 years and 
it is rare below 35years and above                 
74 years14, 15. The increased incidence of MM 
among patients from West of Sudan (Darfur 
and Kurdfan) can be attributed to 
environmental, social and genetic factors. The 
study demonstrated that the farmers and 
patients with free work had high incidence of 
MM. This may be explained by prolong 
exposure and contact to chemicals that have 
been linked to development of multiple 
myeloma including a variety of pesticides and 
herbicides (e.g., organophosphates), and 
wood preservatives. A population-based case-
control study in Japan identified numerous 
occupations associated with significant 
increased risk of multiple myeloma, including 
architects, engineers and related technicians, 
cooks, waiters, bartenders and others, also 
increased risk of MM had been noted in 
atomic bomb survivors in Japan exposed to 
more than 50rad 16. 
Although cerebral disorders, cranial nerves 
are the most frequent neurological 
manifestations17, none of our patients had 
cerebral disorders or cranial nerves 
involvement. Low backache and neck pain 
were the common presenting symptoms 
(38%). As in literature spinal cord 
compression, radiculopathy, and peripheral 
neuropathy were seen in our patients17, 18.  
Our data showed that, low  backache, 
headache, bone pain and weight loss were 
common presenting symptoms among 
patients with multiple myeloma reflecting 
what was mentioned in the literature19-21. 
Among our studied group the renal system 
was the most common system involved by 
MM, followed by locomotor system and this 
is related to the infiltration of plasma cells 
into the kidneys and bones by excess light 
chains22, 23.  
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Central particularly cerebral disorders and 
peripheral nervous systems were affected by 
MM and these may manifest clinically. 
Pathological fracture resulting in spinal cord 
compression can be a presenting feature of 
MM 17, 18.   
Hyperviscosity syndrome affects 8% to 39% 
of patients with MM and may present 
clinically with headache, dizziness, vertigo 
and on occasions can ends with severe 
ischemia24, 25. 
A considerable number of our patients had 
low haemoglobin and high ESR, this is 
similar to what was reported by other 
researchers.26,27 Chronicity of the disease and 
bone marrow involvement especially in late 
stages of the disease, like in our patients, may 
explain low haemoglobin results. About 62% 
of our patients had high serum protein 
and24% had Bence Jones protein, so the 
correlation between the disease extension and 
progression is not so clear.     
 
Conclusion 
Multiple myeloma affects males more than 
females in our studied group. West of Sudan 
has higher incidence of multiple myeloma 
than other states of Sudan with no clear cause. 
The most common presenting symptoms were 
lower backache, bone pain, weight loss and 
lower limbs weakness and numbness, while 
paraplegia was found to be the most common 
neurological presentation in our patients. 
Further researches are needed to demonstrate 
exact incidence and prevalence of multiple 
myeloma in Sudan.  
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